Search results
Results from the WOW.Com Content Network
Five Prime Therapeutics (NASDAQ: FPRX) shares are trading higher on Monday after Wedbush upgraded the company's stock from Neutral to Outperform and raised its price target from $5 to $9.Five ...
Change is in the air. A new President-elect and the possibility of an end to the pandemic. Some things, however, will always stay the same.Like small cap biotech stocks skyrocketing following the ...
Do the numbers hold clues to what lies ahead for the stock? Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended ...
Amgen has agreed to snap up clinical-stage biotech Five Prime Therapeutics for an equity value of $1.9 billion, to strengthen the company’s oncology candidates. Five Prime shares surged 78.7% to ...
For premium support please call: 800-290-4726 more ways to reach us
2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion. [93] [94] [95] In the same month, Amgen acquired Rodeo Therapeutics for $720 million. [96] [97] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us